Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

11.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.4K
GPCR Desensitization01:12

GPCR Desensitization

8.1K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
8.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.8K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.8K
Extraction: Advanced Methods00:56

Extraction: Advanced Methods

1.1K
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
1.1K
Overview of Advanced Functional Groups02:22

Overview of Advanced Functional Groups

29.7K

Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
29.7K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural basis for the synaptic adhesion protein ELFN1-mediated modulation of mGlu7.

Protein & cell·2026
Same author

Subtype-dependent arrestin engagement of the metabotropic glutamate receptors.

Nature communications·2026
Same author

Ligand binding modes of the bitter taste receptor T2R14 and T2R46.

Nature structural & molecular biology·2026
Same author

Rising Stars: Molecular Mechanisms of Ligand Recognition and Functional Modulation of GPCRs.

Journal of molecular biology·2026
Same author

Extra-helical allosteric binding site of apomorphine in ADGRG6.

Cell discovery·2026
Same author

Molecular insights into ligand recognition and receptor activation of GPR15.

iScience·2025

Related Experiment Video

Updated: Jan 28, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.3K

Advancing Chemokine GPCR Structure Based Drug Discovery.

Suwen Zhao1, Beili Wu2, Raymond C Stevens1

  • 1iHuman Institute, ShanghaiTech University, Shanghai 201210, China; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.

Structure (London, England : 1993)
|March 7, 2019
PubMed
Summary

Researchers uncovered the structural basis for inhibiting a human chemokine receptor using a small-molecule antagonist. This finding advances drug design for G-protein-coupled receptors.

More Related Videos

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.2K
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

14.5K

Related Experiment Videos

Last Updated: Jan 28, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.3K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.2K
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

14.5K

Area of Science:

  • Biochemistry
  • Structural Biology
  • Pharmacology

Background:

  • Chemokine receptors are crucial drug targets.
  • G-protein-coupled receptors (GPCRs) represent a large family of cell surface receptors.
  • Understanding receptor-ligand interactions is key for drug development.

Purpose of the Study:

  • To elucidate the structural mechanisms of small-molecule antagonist inhibition of a human chemokine receptor.
  • To provide insights into the drug design principles for chemokine G-protein-coupled receptors.

Main Methods:

  • X-ray crystallography was used to determine the structure of the receptor-antagonist complex.
  • Structure-based computational modeling was employed to analyze binding interactions.

Main Results:

  • The study reveals the precise binding mode of the small-molecule antagonist.
  • Key structural features mediating inhibition were identified.
  • The findings offer a detailed atomic-level understanding of the interaction.

Conclusions:

  • The structural insights advance the rational design of novel therapeutics targeting chemokine GPCRs.
  • This work provides a foundation for developing more effective drugs for various diseases.
  • The study highlights the importance of structural biology in modern drug discovery.